Submitted for Publication: November 10, 2014; final revision received January 29, 2015; accepted January 30, 2015.
Published Online: June 17, 2015. doi:10.1001/jamapsychiatry.2015.0125.
Study concept and design: Lubberink, Fredrikson, Furmark.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Frick, Åhs, Engman, Fredrikson, Furmark.
Critical revision of the manuscript for important intellectual content: Frick, Engman, Jonasson, Alaie, Björkstrand, Frans, Faria, Linnman, Appel, Wahlstedt, Lubberink, Fredrikson, Furmark.
Statistical analysis: Frick, Fredrikson, Furmark.
Obtained funding: Fredrikson, Furmark.
Administrative, technical, or material support: Linnman, Lubberink.
Study supervision: Lubberink, Fredrikson, Furmark.
Conflict of Interest Disclosures: None reported.
Funding/Support: This study was supported by the Swedish Research Council, the Swedish Brain Foundation, Riksbankens Jubileumsfond–the Swedish Foundation for Humanities and Social Sciences, and the Swedish Research Council for Health, Working Life, and Welfare. Ligand production of 5-hydroxytryptophan for the patients was supported by GlaxoSmithKline.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank all the study participants and the staff at the Uppsala positron emission tomography center for their assistance in data collection.